Bristol Myers Squibb, an American pharmaceutical company, completed the acquisition of Forbius, a privately held, clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. Financial terms were not disclosed. "Our portfolio of highly selective TGF-beta inhibitors has shown potential across a broad range of therapeutic areas. We are proud that Bristol Myers Squibb recognizes this potential given their global leadership in oncology and unique position to translate innovative science into meaningful treatments for patients with cancer across the globe," Ilia A. Tikhomirov, Forbius President and CEO.